805 related articles for article (PubMed ID: 24565522)
41. pH-sensitive Laponite(®)/doxorubicin/alginate nanohybrids with improved anticancer efficacy.
Gonçalves M; Figueira P; Maciel D; Rodrigues J; Qu X; Liu C; Tomás H; Li Y
Acta Biomater; 2014 Jan; 10(1):300-7. PubMed ID: 24075886
[TBL] [Abstract][Full Text] [Related]
42. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract][Full Text] [Related]
43. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
[TBL] [Abstract][Full Text] [Related]
44. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
45. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
46. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules.
Chavanpatil MD; Khdair A; Panyam J
Pharm Res; 2007 Apr; 24(4):803-10. PubMed ID: 17318416
[TBL] [Abstract][Full Text] [Related]
47. Polyethylenimine modified liposomes as potential carriers for antitumor drug delivery in vitro.
Sun X; Chen J; Chen H; Liang W
Pharmazie; 2012 May; 67(5):426-31. PubMed ID: 22764577
[TBL] [Abstract][Full Text] [Related]
48. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
[TBL] [Abstract][Full Text] [Related]
49. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours.
Harrington KJ; Rowlinson-Busza G; Uster PS; Stewart JS
Cancer Chemother Pharmacol; 2000; 46(1):10-8. PubMed ID: 10912572
[TBL] [Abstract][Full Text] [Related]
50. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer.
Xiong Y; Zhao Y; Miao L; Lin CM; Huang L
J Control Release; 2016 Dec; 244(Pt A):63-73. PubMed ID: 27840166
[TBL] [Abstract][Full Text] [Related]
51. Preparation and evaluation of a novel liposomal formulation of cisplatin.
Zhou X; Wang J; Wu J; Yang X; Yung BC; Lee LJ; Lee RJ
Eur J Pharm Sci; 2015 Jan; 66():90-5. PubMed ID: 25446511
[TBL] [Abstract][Full Text] [Related]
52. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation.
Qiu L; Zhou C; Sun Y; Di W; Scheffler E; Healey S; Kouttab N; Chu W; Wan Y
Int J Oncol; 2006 Oct; 29(4):1003-11. PubMed ID: 16964397
[TBL] [Abstract][Full Text] [Related]
53. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
[TBL] [Abstract][Full Text] [Related]
54. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y
Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533
[TBL] [Abstract][Full Text] [Related]
55. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
56. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
57. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and toxicity of cisplatin liposomes modified with polyethylenimine.
Sun X; Chen J; Gu X; Liang W; Wang J
Pharmazie; 2014 Apr; 69(4):281-6. PubMed ID: 24791592
[TBL] [Abstract][Full Text] [Related]
59. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.
Zhang N; Dai L; Qi Y; Di W; Xia P
Int J Oncol; 2013 Jun; 42(6):2053-9. PubMed ID: 23592281
[TBL] [Abstract][Full Text] [Related]
60. Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer.
Bansal D; Gulbake A; Tiwari J; Jain SK
Int J Biol Macromol; 2016 Jan; 82():687-95. PubMed ID: 26464131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
